EGFR and breast cancer: In breast cancer again, a cancer gene expression profile that identifies a worse prognosis [13,14] has been approved by the FDA (US Food and Drug Administration) as a method to support clinical decision making, and it is now clear which patients can benefit from treatment with trastuzumab based on epidermal growth factor receptor (EGFR) status.